Table 4. Cytotoxicity of 1a–ta,b.
| test compound | DU145 | HepG2 | B16 | CHO–K1 |
|---|---|---|---|---|
| 1a | 5.24 ± 0.67 | 4.62 ± 0.03 | 9.88 ± 1.19 | 29.32 ± 0.40 |
| 1b | 15.04 ± 1.02 | 7.18 ± 1.89 | 13.39 ± 1.01 | 31.39 ± 0.05 |
| 1c | 2.02 ± 0.74 | 5.47 ± 0.56 | 36.03 ± 1.09 | 16.24 ± 0.93 |
| 1d | 5.10 ± 0.26 | 4.93 ± 1.04 | 5.31 ± 0.07 | 18.63 ± 0.48 |
| 1e | 11.99 ± 0.46 | 8.27 ± 1.03 | 8.89 ± 0.26 | 16.82 ± 0.66 |
| 1f | 5.58 ± 0.17 | 4.23 ± 1.09 | 4.40 ± 0.35 | 6.13 ± 1.19 |
| 1g | 8.13 ± 0.77 | 6.33 ± 1.8 | 9.82 ± 0.52 | 46.55 ± 0.59 |
| 1h | 16.79 ± 0.65 | 6.23 ± 1.6 | 8.17 ± 0.37 | 11.60 ± 1.27 |
| 1i | 10.28 ± 0.87 | 7.43 ± 1.6 | 15.93 ± 0.25 | 13.53 ± 0.73 |
| 1j | 9.46 ± 1.23 | 5.24 ± 0.1 | 9.90 ± 1.61 | 6.38 ± 0.55 |
| 1k | 1.09 ± 0.92 | 5.28 ± 0.24 | 29.24 ± 2.38 | 26.8 ± 1.29 |
| 1l | 91.35 ± 0.81 | 9.73 ± 1.4 | 23.30 ± 0.65 | 24.23 ± 0.68 |
| 1m | 8.18 ± 0.74 | 7.54 ± 1.19 | 9.49 ± 1.97 | 16.5 ± 0.88 |
| 1n | 6.87 ± 1.06 | 11.9 ± 0.10 | 13.6 ± 0.92 | 12.36 ± 1.38 |
| 1o | 60.81 ± 1.24 | 5.87 ± 0.30 | 16.14 ± 0.79 | 10.12 ± 0.75 |
| 1p | 19.36 ± 0.88 | 11.39 ± 1.37 | 19.65 ± 0.87 | 30.49 ± 1.73 |
| 1q | 39.52 ± 1.02 | 5.00 ± 0.01 | 23.5 ± 7.0 | 9.18 ± 1.58 |
| 1r | 21.23 ± 2.01 | 5.82 ± 0.5 | 15.68 ± 2.10 | 30.46 ± 0.33 |
| 1s | 22.62 ± 0.98 | 7.01 ± 0.53 | 7.02 ± 0.32 | 15.84 ± 0.52 |
| 1t | 12.21 ± 0.96 | 8.12 ± 0.87 | 8.14 ± 1.45 | 15.21 ± 0.35 |
| standard (doxorubicin) | 0.7 ± 0.13 | 0.6 ± 0.12 | 0.8 ± 0.12 | |
| standard (Mitomycin C) | 13.3 ± 0.68 |
a
IC50 values (μM) (mean ± S.D.).
b
DU 145 -Prostate cancer cell lines; HepG2-Liver hepato cellular carcinoma cells; B16 -Melanoma cancer cell lines; CHO–K1-Chinese hamster ovary cells (normal).